HCW Biologics Inc. (HCWB): R&D Expense
$5.44M
Year ended 2025-12-31
$5.20M
Trailing 12 months to 2026-06-30
-16.5%
3-year compound annual growth
-5.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.44M | -14.8% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $6.39M | -16.8% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $7.68M | -17.8% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $9.34M | +14.2% | 2024-05-15, From 2022-01-01 |
| 2021-12-31 | $8.17M | +12.7% | 2023-03-28, From 2021-01-01 |
| 2020-12-31 | $7.26M | n/a | 2022-03-29, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $5.44M | -14.8% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $50.08M | +105.0% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $37.80M | +29.2% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $54.21M | -28.3% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $66.43M | -19.2% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $2.16M | -8.8% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $158.68M | -7.5% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $10.75M | -16.6% |
Compare HCWB, AVTX, CNTB, INO side by side · Screen every company in Pharmaceutical Preparations ↗